The US cannabis industry could be in for a “nuclear winter” over at least the first half of 2023, according to Roth Capital Partners, which published an Industry Note on Monday, as macro and structural headwinds look likely to prevail across the sector. But Roth analyst Scott Fortune is still bullish on a number of […]
MariMed has a 167 per cent upside, says EchelonA new credit facility comes at a great time for US cannabis name MariMed Inc (MariMed Stock Quote, Charts, News, Analysts, Financials OTC:MRMD), according to Echelon Capital Markets analyst Andrew Semple, who provided an update to clients on Monday. Semple said the debt financing is a savvy move by MariMed to bolster its balance sheet […]